Form 4: Boundless Bio CFO Jami Rubin Reports Stock Option Grant
SEC Form 4 Filing
Jami Rubin, CFO of Boundless Bio, Inc., reports the acquisition of stock options.
Summary
- Jami Rubin, the Chief Financial Officer of Boundless Bio, Inc., filed a Form 4 with the SEC.
- The filing reports the acquisition of 32,468 stock options on March 27, 2024.
- The stock options have an exercise price of $16.
- The options vest in 48 substantially equal monthly installments beginning on April 27, 2024, and expire on March 26, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing and does not contain information that would significantly impact sentiment positively or negatively.
Positives
- The grant of stock options to the CFO aligns her interests with those of the shareholders.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock price.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Regeneron also utilize stock options to incentivize their executives.
- The vesting schedule of 48 months is fairly standard.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of stock option transaction |
| 04/27/2024 | Vesting start date for stock options |
| 03/26/2034 | Expiration date for stock options |
| 03/29/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.